No. 20-1069

Janssen Pharmaceuticals, Inc., et al. v. A. Y., et al.

Lower Court: Pennsylvania
Docketed: 2021-02-05
Status: Denied
Type: Paid
Amici (4) Experienced Counsel
Tags: civil-liability drug-labeling fda-regulation federal-preemption impossibility-preemption off-label-use preemption state-tort-law
Key Terms:
Environmental SocialSecurity Securities Immigration
Latest Conference: 2021-05-13
Question Presented (AI Summary)

Whether federal law preempts state-law claims that a manufacturer failed to provide adequate warnings relating to the off-label use of their products, where federal law bars the manufacturer from unilaterally altering its labeling to provide such warnings

Question Presented (OCR Extract)

QUESTION PRESENTED Off-label use of prescription drugs is an accepted and beneficial feature of medical practice, but federal law bars drug manufacturers from—and imposes significant civil and criminal penalties for—promoting their drugs for off-label use. 21 U.S.C. §§331(a), 333(a), 352(a) & (f). The FDA accordingly prohibits manufacturers from making unsolicited statements— including warnings in their FDA-approved labeling— about off-label uses, which impliedly promote such uses as safe and effective. By law, only the FDA may impose such a warning: a “specific warning relating to a use not provided for under the [product’s labeling] may be required by Food and Drug Administration,” but only after it determines the “drug is commonly prescribed” off-label and such “usage is associated with a clinically significant risk or hazard.” 21 C.F.R. §201.57(e) (2003) (emphasis added). Petitioner Janssen Pharmaceuticals markets Risperdal, a highly effective treatment for psychotic disorders that, until 2006, was approved only for adults but also prescribed off-label for children. The court below misapplied this Court’s decision in Wyeth v. Levine, 555 U.S. 555 (2009)—which concerned warnings for on-label uses—to hold Petitioners liable under state tort laws for failing to unilaterally add warnings about Risperdal’s off-label use in children. The decision below exposes Petitioners (and every drug manufacturer) to unendurable liability for failing to do precisely what federal law prohibits. This is the paradigm of impossibility preemption. The question presented is: Whether federal law preempts state-law claims ii that a manufacturer failed to provide adequate warnings relating to the off-label use of their products, where federal law bars the manufacturer from unilaterally altering its labeling to provide such warnings.

Docket Entries

2021-05-17
Petition DENIED. Justice Alito took no part in the consideration or decision of this petition.
2021-04-21
DISTRIBUTED for Conference of 5/13/2021.
2021-04-21
Reply of petitioners Janssen Pharmaceuticals, Inc., et al. filed. (Distributed)
2021-04-07
Brief of respondents A.Y. and Billy Ann Yount in opposition filed.
2021-03-08
Brief amici curiae of Pharmaceutical Research and Manufacturers of America, Chamber of Commerce of the United States of America, and American Tort Reform Association filed.
2021-03-08
Brief amici curiae of National Association of Manufacturers and International Association of Defense Counsel filed.
2021-03-05
Brief amicus curiae of Washington Legal Foundation filed.
2021-03-04
Brief amicus curiae of Product Liability Advisory Council, Inc. filed.
2021-02-12
Motion to extend the time to file a response is granted and the time is extended to and including April 7, 2021.
2021-02-11
Motion to extend the time to file a response from March 8, 2021 to April 7, 2021, submitted to The Clerk.
2021-01-29
Petition for a writ of certiorari filed. (Response due March 8, 2021)

Attorneys

A.Y. and Billy Ann Yount
Charles Lyman BeckerKline & Specter, P.C., Respondent
Charles Lyman BeckerKline & Specter, P.C., Respondent
Janssen Pharmaceuticals, Inc., et al.
Jay Philip LefkowitzKirkland & Ellis LLP, Petitioner
Jay Philip LefkowitzKirkland & Ellis LLP, Petitioner
National Association of Manufacturers and International Association of Defense Counsel
Eric G. LaskerHollingsworth LLP, Amicus
Eric G. LaskerHollingsworth LLP, Amicus
Pharmaceutical Research and Manufacturers of America, Chamber of Commerce of the United States of America, and American Tort Reform Association
Michael Xavier ImbroscioCovington and Burling LLP, Amicus
Michael Xavier ImbroscioCovington and Burling LLP, Amicus
Product Liability Advisory Council, Inc.
James M. BeckReed Smith LLP, Amicus
James M. BeckReed Smith LLP, Amicus
Washington Legal Foundation
John Mercer Masslon IIWashington Legal Foundation, Amicus
John Mercer Masslon IIWashington Legal Foundation, Amicus